1.Stahl, SM, Wets, KM. Recent advances in drug delivery technology for neurology. Clin Neuropharmacol. 1988; 11(1): 1–17.
2.Stahl, SM. At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. J Clin Psychiatry. 2003; 64(4): 355–356.
3.Chen, ML, Shah, VP, Ganes, D, et al. . Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified-release products: workshop summary report. Eur J Pharmaceutical Sci. 2010; 40: 148–153.
4.Brannon-Peppas, L. Preparation and characterization of crosslinked hydrophilic networks. In: Absorbent polymer technology. Amsterdam: Elsevier; 1990. pp. 45–66.
5.Colombo, P, Bettini, R, Santi, P, Peppas, NA. Swellable matrices for controlled drug delivery: gel-layer behavior, mechanisms and optimal performance. Pharm Sci Technolo Today. 2000; 3(6): 198–204.
6.Wen, H, Park, K. Oral controlled release formulation design and drug delivery: theory to practice, Hoboken, New Jersey: John Wiley & Sons, Inc.; 2010.
7.Tiwari, SB, Rajabi-Siahboomi, AR. Extended-release oral drug delivery: technologies: monolithic matrix systems. Methods Mol Biol. 2008; 437: 217–243.
8.Frutos, P, Pabon, C, Lastres, JL, Frutos, G. In vitro release of metoclopramide from hydrophobic matrix tablets. Influence of hydrodynamic conditions on kinetic release parameters. Chem Pharm Bull. 2001; 49(10): 1267–1271.
9.Roy, P, Shahiwala, A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. J Controlled Release. 2009; 134: 74–80.
10.Siepmann, F, Hoffman, A, Leclercq, B, Carlin, B, Siepmann, J. How to adjust desired drug release patterns from ethylcellulose-coated dosage forms. J Controlled Release. 2007; 119: 182–189.
11.Felton, LA. Characterization of coating systems. AAPS PharmSciTech. 2007; 8(4): E1–E9.
12.Ball, AM, Smith, KM. Optimizing transdermal drug therapy. Am J Health Syst Pharm. 2008; 65(14): 1337–1346.
13.Keith, S. Advances in psychotropic formulations. Prog Neuro-psychopharmacol Biol Psychiatry. 2006; 30: 996–1008.
14.Muramatsu, RS, Litzinger, MHJ, Fisher, E, Takeshita, J. Alternative formulations, delivery methods, and administration options for psychotropic medications in elderly patients with behavioral and psychological symptoms of dementia. Am J Geriatr Pharmacother. 2010; 8(2): 98–114.
16.U.S. Food and Drug Administration Center for Drug Evaluation and Research. Approved drug products with therapeutic equivalence evaluations. 31st ed.; 2011.
17.Sankar, R, Glauser, TA. Understanding therapeutic equivalence in epilepsy. CNS Spectr. 2010; 15(2): 112–123.
18.Wilner, AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004; 5: 995–998.
19.Gilman, JT, et al. . Carbamazepine toxicity resulting from generic substitution. Neurology. 1993; 43: 2696–2697.
20.Chenu, F, et al. . Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry. 2009; 70(7): 958–966.
22.Desmarais, JE, Beauclair, L, Marolese, HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neurosci Ther. 2010; Epub ahead of print.
23.Endrenyi, L, Tothfalusi, L. Do regulatory bioequivalence requirements adequately reflect the therapeutic equivalence of modified-release drug products? J Pharm Pharmaceut Sci. 2010; 13(1): 107–113.
24.Raw, AS, Lionberger, R, Yu, LX. Pharmaceutical equivalence by design for generic drugs: modified-release products. Pharm Res. 2011; 28: 1445–1453.